Key Highlights
● The LS&H sale closed October 6 with $488.4 million in net cash proceeds.
● Continuing-operations Revenue was $481.6 million, down 9.2%.
● Adjusted EBITDA from continuing operations was $218.2 million.
● Total Debt was $4,176.1 million, down $293.8 million year over year.
Clarivate Plc (NYSE:CLVT) is in focus after reporting third-quarter 2026 results on November 3 and completing the sale of its Life Sciences & Healthcare (LS&H) Business on October 6. The divestiture produced net cash proceeds of $488.4 million and leaves the information services company concentrated on Academia & Government and Intellectual Property. For investors following data and analytics providers, the portfolio reshaping, debt reduction and updated guidance are the main storylines going into the end of the year.
Latest Company Context
Third-quarter revenue from continuing operations, which excludes LS&H, was $481.6 million, down 9.2%, with organic growth of 0.4%. Including LS&H, revenue was $567.9 million. The company reported a net loss of $80.8 million, or $0.13 per share, including a $62.2 million non-cash Goodwill Impairment related to LS&H. Adjusted EBITDA from continuing operations was $218.2 million versus $222.2 million. Organic annual contract value grew 1.8% and total ACV grew 3.6%. Total debt was $4,176.1 million at September 30, down $293.8 million from a year earlier, and share repurchases were $18.1 million in the first nine months versus $149.5 million a year earlier.
Key Business and index Drivers
Management's 2026 guidance for continuing operations includes revenue of $1.965 billion to $1.985 billion, adjusted EBITDA of $865 million to $885 million, adjusted diluted EPS of $0.73 to $0.77, free Cash Flow of $320 million to $340 million and organic ACV growth of 1.75% to 2.25%. The company said its outlook assumes no further acquisitions or divestitures. Management described the company as positioned for enhanced value creation in its two remaining segments. Key drivers include subscription renewals and pricing, the conversion of ACV into recognized revenue, and how the LS&H proceeds are deployed, whether toward debt reduction, Buybacks or other uses, which the release does not specify beyond the debt actions already completed.
What Investors Should Watch
Investors may watch the fourth-quarter guidance, which calls for revenue of $490 million to $510 million, adjusted EBITDA of $215 million to $235 million and free cash flow of $85 million to $105 million. Use of the $488.4 million in divestiture proceeds is a key question, given the company's debt load. Organic ACV trends are likely to stay in focus because they feed future revenue growth. Further portfolio moves are not assumed in guidance, so any announcement would be a change from the current framework. Analyst expectations may shift after the results, but they are estimates and not company guidance.
Possible scenarios differ. If proceeds are applied largely to debt, interest costs could decline over time; if used for repurchases or other priorities, the balance-sheet effect may differ. Management has not specified a full allocation in the release, so any view is speculative. Investors may also track how the remaining Academia & Government and Intellectual Property businesses perform on a stand-alone basis, since their combined growth profile is now the foundation for the guidance. Subscription-based models can be steady, but renewal rates and pricing remain variables worth following in upcoming reports and investor presentations.
Portfolio Reset Leaves Debt in View
Clarivate has completed a significant portfolio change and returned to modest organic growth on a continuing basis, while still carrying a substantial debt balance and a net loss that includes non-cash impairments. The coming quarters may show how effectively the leaner business converts ACV growth into Earnings and cash flow.





_11_18_2026_15_37_14_813718.jpg)
Please wait processing your request...